产品说明书
Vonafexor
 |
同义名 : | EYP001;PLX007 |
| CAS号 : | 1192171-69-9 | |
| 货号 : | A1281092 | |
| 分子式 : | C19H15Cl3N2O5S | |
| 纯度 : | 99%+ | |
| 分子量 : | 489.757 | |
| MDL号 : | MFCD32701906 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 85 mg/mL(173.56 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Vonafexor is a new non bile acid, selective second generation farnesoid X receptor (FXR) agonist. Vonafexor was safe and had a potential anti-viral effect with a decline in HBV markers observed in CHB (chronic hepatitis B) patients. Vonafexor monotherapy of 400 mg once daily decreased HBsAg concentrations, and Vonafexor/pegylated-IFN-α2a combination therapy decreased HBcrAg and pgRNA[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.04mL 0.41mL 0.20mL |
10.21mL 2.04mL 1.02mL |
20.42mL 4.08mL 2.04mL |
| 参考文献 |
|---|